The Imitation Vaccine (06660) iterative process is highly cost-effective and the human diploid vaccine submits an application for marketing registration, leading technical advantages

The Zhitong Finance App learned that the Emmy Vaccine (06660) announced on August 24 that the company's self-developed iterative process for the highly cost-effective human diploid rabies vaccine has submitted an application for marketing registration to the State Drug Administration. This market-competitive mad seedling is about to be registered and listed. Together with Aimee's Serum-free Iterative Mad Seedling and Vero Cell Crazy Seedling, they will build an iterative product portfolio to seize the market advantage.

According to the results of phase III clinical trials that have completed decontamination, Aimei's iterative process is highly cost-effective for human diploid vaccine, which has good safety, immunogenicity, and immune persistence. Immunogenicity and immune persistence are superior to similar control vaccines, and all indicators fully meet the evaluation standards set in clinical trials.

Wu Jinan, the honorary general manager of Emmy, once publicly explained, “I am very confident about this human diploid rabies vaccine. It should be the rabies vaccine with the most advanced domestic production process, the best quality in terms of efficacy and safety, and the most convenient to administer.”

Faced with fierce market competition, Wu Jinan believes that new opportunities lie in the immunization procedure, that is, “how many injections” and “how long.” Currently, most of the immunization procedures for rabies vaccines on the market are completed within three or four weeks, and there is plenty of room for optimization of vaccination methods. The Aimei vaccine can be vaccinated using a simple four-dose method and a 2-1-1 four-dose method, which is more compliant with patients. Based on this, its competitive strength and development space are worth looking forward to.

Rabies is a disease with a high fatality rate in the world. Once it develops, the fatality rate is close to 100%. Currently, there is a lack of effective treatments for rabies clinically, and prevention will be a long-term need. As the second largest rabies vaccine supplier in the world, Le Méridien is committed to leading the in-depth technical iteration of the global rabies vaccine, providing the market with a series of rabies vaccine products with better quality and higher safety, and further consolidating the company's leading position in the global rabies vaccine field.

With the approval of the highly cost-effective human diploid vaccine in an iterative process, it will collaborate with the existing rabies vaccine series to enhance the core competitiveness of the company's mad vaccine products and consolidate its leading position. At the same time, as part of the global layout, it can contribute additional revenue, strengthen Aimee's market position, and add new momentum to its continued steady development.